Gene and protein sequence features augment HLA class I ligand predictions
K. Bresser, B. Nicolet, A. Jeko, W. Wu, F. Loayza-Puch, R. Agami, A. J. R. Heck, M. J. R. Wolkers, T. Schumacher
Abstract
The sensitivity of malignant tissues to T cell-based cancer immunotherapies is dependent on the presence of targetable HLA class I ligands on the tumor cell surface. Peptide intrinsic factors, such as HLA class I affinity, likelihood of proteasomal processing, and transport into the ER lumen have all been established as determinants of HLA ligand presentation. However, the role of sequence features at the gene and protein level as determinants of epitope presentation has not been systematically evaluated. To address this, we performed HLA ligandome mass spectrometry on patient-derived melanoma lines and used this data-set to evaluate the contribution of 7,124 gene and protein sequence features to HLA sampling. This analysis reveals that a number of predicted modifiers of mRNA and protein abundance and turn-over, including predicted mRNA methylation and protein ubiquitination sites, inform on the presence of HLA ligands. Importantly, integration of gene and protein sequence features into a machine learning approach augments HLA ligand predictions to a comparable degree as predictive models that include experimental measures of gene expression. Our study highlights the value of gene and protein features to HLA ligand predictions.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- EPIP: MHC-I epitope prediction integrating mass spectrometry derived motifs and tissue-specific expression profiles
Weipeng Hu, Si Qiu, … Leo J. Lee·bioRxiv·Aug 24, 2020
- Mass spectrometry based immunopeptidomics leads to robust predictions of phosphorylated HLA class I ligands
M. Solleder, P. Guillaume, … D. Gfeller·bioRxiv·Nov 9, 2019
- Identification of tumor-specific MHC ligands through improved biochemical isolation and incorporation of machine learning
S. Mecklenbräuker, P. Skoczylas, … M. G. Klatt·bioRxiv·Jun 8, 2023
- Immunogenicity of non-canonical HLA-tumor ligands identified through proteogenomics
M. Lozano-Rabella, A. Garcia-Garijo, … A. Gros·Clinical Cancer ResearchPeer-reviewed·Feb 7, 2023
- A peptide-signal amplification strategy for the detection and validation of neoepitope presentation on cancer biopsies
S. H. Ramarathinam, P. Faridi, … A. W. Purcell·bioRxiv·Jun 12, 2020
- Proteogenomic analysis unveils the HLA Class I presented immunopeptidome in melanoma and EGFR mutant lung adenocarcinoma
Y. A. Qi, T. K. Maity, … U. Guha·bioRxiv·Aug 4, 2020